NANOLOGIX IS A BIOTECHNOLOGY COMPANY specializing in rapid diagnostics tools for biodefense, medical, environmental, and industrial uses.
The primary focus of NanoLogix is rapid detection of bacteria and other microorganisms.
Stock Symbol NNLX.pk
Our BNP™ ultra-fast test kit sets a new standard for accurate, high-speed diagnostics. With results two to four times faster than traditional Petri dish methods, NanoLogix technology represents a revolutionary next step in microorganism identification.
Uses for NanoLogix’s very-rapid diagnostics include biodefense, human and veterinary medicine, processing and safety of food, cosmetics and drugs, research and development, and industrial and environmental testing. Rapid detection of microorganisms is an annual multi-billion dollar market.
NanoLogix has been issued 33 patents in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation.
See the Products page to explore our new BNP™ technology.
Please contact us for more information.
TIME TO DETECTION
Comparison of BNP™ with traditional petri dish technology
| Microorganism | Traditional time range for observance of cultures (hours) | Average time with BNP™ (hours)* |
|---|---|---|
| Bacillus anthracis | 24 | 6* |
| Yersinia pestis | 48 | 24* |
| Salmonella enterica | 24 | 5* |
| Escherichia coli | 18 - 24 | 4* |
| Staphylococcus aureus | 18 - 24 | 4* |
| Pseudomonas aeruginosa | 18 - 24 | 5* |
| Streptococcus pyogenes | 18 - 24 | 5* |
| Assorted yeasts | 48 - 72 | 12 - 16* |
| Entherobacter cloaceae | 24 | 5 - 6* |
| Listeria inocula | 18 - 24 | 5* |
| Klebsiella pneumonia | 24 | 6* |
*"Average time with BNP™" results are based upon results actually achieved by NNLX through internal testing or results reported from independent third party tests. Detection time depends upon environmental conditions, sample quality, microorganism growth rates, nutrient concentrations, and many other factors. Actual results may vary.
Updates
Wednesday, June 30, 2010
NanoLogix has filed and received medical device registration approval from the U.S. FDA for their BNP™ BNF™ and BNC™ test kits. Registration number: 3005553828.
Thursday, June 24, 2010
The Company has received the remaining 10 machines ordered from New Brunswick Scientific. 'NBS' personnel will be in-house June 29 to complete setup and inspection of the equipment.
Tuesday, June 22, 2010
Our collaboration with the Texas Medical Center has produced preliminary culture-based results for the rapid detection of Group-B Streptococcus of between 4-6 hours. The initial results are 12-18 times faster than the 72 hour wait time experienced with traditional petri technology. The Texas Medical Center is continuing to finalize these Group-B Strep results and NanoLogix is furnishing additional test kits for that purpose.
Thursday, June 10, 2010
Link to June 7th, 2010 Vindicator article.
Thursday, May 20, 2010
The company is negotiating to purchase its corporate headquarters and clean room production facility from the current owners. In addition, NanoLogix has raised approximately $1.4 million since the beginning of 2010 in private placement funds. This provides basic operating capital for the company for the next three years. All funds were raised through the sale of restricted shares with a focus on minimal dilution.
Tuesday, May 18, 2010
NanoLogix Inc. Explores Rapid Detection Applications For Required Tests of 4.3 Million Pregnancies A Year
Read More